Oncopeptides to Present New European Real-World Evidence for Pepaxti in Multiple Myeloma at ASH 2026
Oncopeptides AB (publ), a biotech company specializing in difficult-to-treat cancers, has announced that two abstracts detailing real-world clinical outcomes for its drug Pepaxti (melflufen) in relapsed, refractory multiple myeloma (RRMM) have been accepted for presentation at the 68th American Society of Hematology (ASH) Annual Meeting. The meeting is scheduled to take place in New Orleans, USA, from December 12–15, 2026. These abstracts are based on two independent multicenter retrospective studies conducted in Spain and Italy, involving a total of 82 heavily pretreated RRMM patients. The studies aim to reinforce the clinical utility and manageable safety profile of Pepaxti when used in combination with dexamethasone in real-world European clinical practice. This includes its application in patients who have previously received T-cell-redirecting immunotherapies, such as anti-BCMA and anti-GPRC5D agents, and as a bridging therapy between immunotherapies.